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Introduction:
Secnidazole is an anti infective agent which belongs to the 5-nitroimidazole class.
Method:
The objective of the trial was to characterize the pharmacokinetics of secnidazole
after oral administration of a 2g dose, as microgranules formulation in healthy
subjects. Blood samples were collected before, 1, 2, 3, 6, 9, 12, 24, 36, 48, 72, 96,
120, 168 and 240 h after dosing. Urines were collected in 24-h-fractions for the first
five days and in 48 h-fraction for the last sample. The cumulative urinary excretion
was captured for each subject from urine concentration (lg/L). Pharmacokinetic
parameters were obtained by a non-compartmental approach (WinNonlin Pharsight).
The assay was performed by ultra-performance liquid chromatography coupled with
mass spectrometry detection (UPLC-MS/MS, Quattro Premier, Waters) after simple
protein precipitation of 50 lL plasma sample. Chromatographic separation was done
on a C18 Acquity column (50 mm · 2.1 mm, id 1.7 lm, Waters), in isocratic mode
(80% water/0.1% formic acid and 20% acetonitrile). Ornidazole was used as internal
standard. The detection was operated in positive mode and multiple reaction
monitoring was used for quantification (186 > 128 ion transition for secnidazole).
The lower limit of quantification was 10 and 100 lg/L for plasma and urine samples
respectively.
Results:
Sixteen subjects (8 female, 8 male) were included. Population characteristics such
as: age ranged from 23 to 50 years (mean ± SD: 38 ± 9.2 years), weight ranged from
51 to 90 Kg (mean ± SD = 64.6 ± 10.1 Kg) and body mass index (BMI) ranged from
19.9 to 24.2 Kg/m 2 (mean ± SD = 21.9 ± 1.5 Kg/m 2 ;). Secnidazole exposure
achieved a maximal concentration (Cmax) with a mean of 37.9 ± 8.5 mg/L (range
20–56 mg/L) and at a median time associated with the Cmax (Tmax) of 6 h (range
3–6 h). The area under the curve to the last measurable time (AUC0_t) and the total
area under the curve (AUC0_¥) were 1281.9 ± 416.4 mg h/L and 1304.2 ± 444.1 mg
h/L (mean ± SD) respectively.
The Cl/F and V/F were 1.7 ± 0.5 L/h and 40.2 ± 9.2 L respectively and the
elimination half-life (t1/2) was 17.5 ± 4.3 h (mean ± SD). The mean amount of
secnidazole excreted in the 168-h urine collection was 310.47 mg (15.5% of the
administered dose). For example, for the subject number 5, the observed parameters
are: Cmax 37.3 mg/L, Tmax 3 h, AUC0_¥ 1029.5 mg h/L and t1/2 15.6 h.
Conclusion:
After a 2 g single oral dose, secnidazole presents a good absorption profile and
relatively long elimination half life ensuring probable sufficient exposure with once a
day administration.
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